目的 建立阿戈美拉汀药物利用评价标准，评价和分析阿戈美拉汀临床应用情况，为临床合理使用提供参考。方法 以阿戈美拉汀说明书为基础，参考相关指南、文献、诊疗规范，建立阿戈美拉汀药物利用评价标准，并以此标准回顾性分析深圳市精神卫生中心2022年1月—2025年6月使用阿戈美拉汀的住院患者进行用药合理性评价。结果 共纳入280份病历，用药适应证符合率为86.07%，不合理应用常见于用药疗程、特殊人群用药。结论 针对阿戈美拉汀在患者治疗过程中出现的问题可作为药学部门积极干预处理的重点，为进一步促进临床合理用药，保障患者用药安全提供参考。

Objective To establish the drug use evaluation (DUE) standard for agomelatine in clinical application, and provide reference for its rational use. Methods Based on the drug instructions of agomelatine, relevant guidelines, literatures, diagnosis and treatment standards, the DUE standard was established ,which was used to evaluate the rationality of drug use among inpatients in the Shenzhen Mental Health Center who received agomelatine from January 2022 to June 2025. Results Total 280 inpatients were included, the coincidence rate of medication indication was 86.07%, irrational use of agomelatine was common in course of medication and medication for special populations. Conclusion The problems in the treatment of patients with agomelatine can be regarded as the focus of intervention, and providing a reference for further promoting rational clinical drug use and ensuring the safety of patients’ medications use.

R971

广东省高水平临床重点专科（深圳市配套建设经费）资助项目（SZGSP013）；深圳市科技创新局项目深圳市精神心理疾病临床医学研究中心建设经费（20210617155253001）